Graph AI raises $13.3 M to accelerate expansion across US and Europe

image credit- freepik

Graph AI, developer of the Graph Safety AI-native patient safety platform, has announced a $13.3 million Series A financing led by Insight Partners, with participation from existing investor Bessemer Venture Partners.

Founded in 2024, Hyderabad-based Graph AI was created to address the operational inefficiencies and regulatory complexity facing modern pharmacovigilance and patient safety teams. Today, pharma teams devote much of their effort towards manual processing and operational workflows.

Graph Safety enables intelligent software to take on that operational load, allowing safety experts to spend more time on analysis, decision-making, and areas where human judgement is essential. Graph Safety combines AI with deterministic controls, validation layers, and end-to-end audit trails designed for regulated pharmacovigilance environments. Output and source data remain traceable, supporting customer validation, inspection readiness, and human oversight.

The platform has been designed with reference to applicable regulatory requirements and evolving expectations for AI in medicines development and patient safety, including the FDA's risk-based credibility assessment framework for AI used to support regulatory decision-making, the EU Artificial Intelligence Act, and the CIOMS Working Group XIV report on Artificial Intelligence in Pharmacovigilance.

In live deployments, Graph Safety has reduced case processing turnaround time from more than three hours to under 10 minutes – a reduction of more than 90% and lowered operating costs by up to 66%.

The company has onboarded pharmaceutical and biotech customers across North America and other markets, and secured design partnerships for the modules ahead, including /signal, which surfaces emerging safety signals and patterns across cases.